Intellia Therapeutics, Inc.
- Open
- 12.53
- Day high
- 12.66
- Day low
- 12.34
- Prev close
- 12.73
- Volume
- 591K
- Mkt cap
- $1.8B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.4
- P/S
- 29.7
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$507K over the last 3 months (0 open-market buys, 5 sales)
- 🏛Institutions accumulating (13F)
Intellia Therapeutics, Inc. (NTLA) is a Healthcare company listed on NASDAQ. The stock is up 11% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 5 sales (SEC Form 4).
Intellia Therapeutics, Inc. (NTLA) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NTLA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.80 | $-0.80 | -0.1% | $8M | -42.7% |
| May 11, 2026 | $-0.92 | $-0.81 | +12.0% | $15M | +6.8% |
| Feb 26, 2026 | $-0.99 | $-0.83 | +16.2% | $23M | +86.3% |
| Nov 6, 2025 | $-1.02 | $-0.92 | +9.8% | $14M | +14.4% |
| Aug 7, 2025 | $-1.03 | $-0.99 | +3.9% | $14M | +4.4% |
| May 8, 2025 | $-1.26 | $-1.10 | +12.7% | $17M | +39.3% |
| Feb 27, 2025 | $-1.32 | $-1.24 | +6.1% | $13M | +18.5% |
| Nov 7, 2024 | $-1.37 | $-1.34 | +2.2% | $9M | +1.0% |
| Aug 8, 2024 | $-1.21 | $-1.31 | -8.3% | $7M | -63.2% |
| May 9, 2024 | $-1.35 | $-1.06 | +21.5% | $29M | +153.6% |
| Feb 22, 2024 | $-1.47 | $-1.46 | +0.7% | $2M | -85.1% |
| Nov 9, 2023 | $-1.52 | $-1.38 | +9.2% | $12M | -4.9% |
NTLA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | LEONARD JOHN Mdirector, officer: President and CEO | Sell | 19,890 | $12.60 |
| Aug 24, 2026 | LEONARD JOHN Mdirector, officer: President and CEO | Sell | 2,785 | $13.00 |
| Jul 24, 2026 | Dulac Edward J IIIofficer: EVP, Chief Financial Officer | Sell | 8,111 | $11.25 |
| Jul 6, 2026 | Dulac Edward J IIIofficer: EVP, Chief Financial Officer | Sell | 4,677 | $18.00 |
| Jul 6, 2026 | Dube Michael Pofficer: VP, Chief Accounting Officer | Sell | 2,641 | $16.78 |
| Jun 10, 2026 | GOODMAN JESSEdirector | Grant | 9,200 | — |
| Jun 10, 2026 | Cohen Fred Edirector | Grant | 9,200 | — |
| Jun 10, 2026 | CHASE WILLIAM Jdirector | Grant | 9,200 | — |
| Jun 10, 2026 | Keresty Georgiadirector | Grant | 13,300 | $12.89 |
| Jun 10, 2026 | CHASE WILLIAM Jdirector | Grant | 13,300 | $12.89 |
| Jun 10, 2026 | Bhanji Munadirector | Grant | 13,300 | $12.89 |
| Jun 10, 2026 | Bhanji Munadirector | Grant | 9,200 | — |
| Jun 10, 2026 | Verwiel Frankdirector | Grant | 9,200 | — |
| Jun 10, 2026 | Goff Briandirector | Grant | 13,300 | $12.89 |
| Jun 10, 2026 | Keresty Georgiadirector | Grant | 9,200 | — |
Source: NTLA SEC Form 4 filings, latest Aug 24, 2026. For informational purposes only — not investment advice.
See the full NTLA insider & 13F page →Intellia Therapeutics, Inc. company profile
Overview
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a genome editing company founded in 2014 and headquartered in Cambridge, Massachusetts. The company went public in May 2016 and focuses on developing revolutionary therapeutic treatments using CRISPR/Cas9 gene editing technology. Intellia has positioned itself as a leader in the emerging field of precision gene editing, developing both in vivo treatments that work directly inside patients' bodies and ex vivo therapies that modify cells outside the body before reintroduction. The company has advanced multiple programs into late-stage clinical trials and is preparing for its first potential commercial launches in the mid-2020s.
Business
Intellia operates in the genome editing biotechnology sector, developing therapeutic treatments that can precisely modify genes to treat or cure genetic diseases. The company's core technology platform is based on CRISPR/Cas9 (Clustered, Regularly Interspaced Short Palindromic Repeats), a revolutionary gene editing system that acts like molecular scissors to cut DNA at specific locations and either remove problematic genes or insert healthy ones. The company operates two main therapeutic approaches. In vivo programs deliver gene editing treatments directly into patients through injections, where the editing occurs inside the body. Ex vivo programs involve removing cells from patients, editing them in the laboratory, then reinfusing the modified cells back into the patient. Intellia's lead programs include: 1. NTLA-2002 for hereditary angioedema (HAE) - a rare genetic disorder causing severe swelling attacks. This program aims to provide a functional cure with a single injection by permanently reducing the protein that causes attacks. 2. Nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin amyloidosis (ATTR) - a progressive disease where misfolded proteins damage organs. The treatment permanently reduces production of the problematic protein. 3. NTLA-3001 for alpha-1 antitrypsin deficiency - a genetic condition affecting lungs and liver. This represents the company's first gene insertion program, designed to restore normal protein production. 4. NTLA-5001 for acute myeloid leukemia - an ex vivo program that engineers immune cells to better fight cancer. The company also maintains research collaborations with major pharmaceutical companies including Novartis and Regeneron to develop additional gene editing therapies across various disease areas.
Revenue model
Intellia generates revenue primarily through collaboration agreements with pharmaceutical partners, receiving upfront payments, milestone payments, and research funding. In 2024, the company reported $57.9 million in collaboration revenue, though this has been declining as partnerships mature. The company has not yet launched commercial products but expects its first commercial revenues from NTLA-2002 for hereditary angioedema in the first half of 2027. The company's future business model will center on product sales of gene editing therapies, which are expected to command premium pricing due to their potential to provide one-time cures rather than chronic treatments. These therapies target rare genetic diseases with limited treatment options, allowing for value-based pricing that reflects the significant clinical benefit and reduced long-term healthcare costs. Key factors that could increase margins include successful clinical outcomes demonstrating superior efficacy compared to existing treatments, regulatory approvals that validate the safety and effectiveness of gene editing approaches, and the company's ability to establish itself as the leading gene editing therapeutics company. The rare disease focus provides pricing power, as these conditions often have few or no effective treatments. Factors that could pressure margins include increased competition from other gene editing companies like Editas Medicine and CRISPR Therapeutics, manufacturing complexity and costs associated with producing personalized gene therapies, potential safety concerns that could slow adoption, and pricing pressure from healthcare payers despite the innovative nature of the treatments. The company also faces the challenge of building commercial infrastructure and competing against established pharmaceutical companies with greater resources and market access capabilities.
Competitive moat
Intellia's competitive moat is moderately strong but faces significant challenges in an rapidly evolving field. The company's primary advantages include its comprehensive intellectual property portfolio around CRISPR/Cas9 technology, particularly for in vivo applications, and its first-mover advantage in several therapeutic areas. The company has demonstrated superior clinical results in some programs, such as achieving deeper and more sustained protein reduction in ATTR amyloidosis compared to competitors. The company's platform approach provides some protection, as success in one program validates the broader technology and creates opportunities to expand into additional diseases. Intellia's partnerships with established pharmaceutical companies like Regeneron and Novartis provide validation and resources that smaller competitors may lack. However, the moat faces considerable threats. The gene editing space is highly competitive, with well-funded rivals including CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics pursuing similar approaches. Large pharmaceutical companies are also developing internal capabilities or acquiring gene editing companies, potentially creating formidable competition. The fundamental CRISPR technology is widely accessible, and the key differentiation often comes down to delivery methods, targeting strategies, and execution rather than proprietary technology. Additionally, the field is still emerging, and breakthrough approaches from competitors could potentially leapfrog Intellia's current advantages. The company's success depends heavily on clinical trial outcomes, regulatory approvals, and the ability to demonstrate superior efficacy and safety compared to both existing treatments and competing gene editing approaches. While Intellia has established a strong position, the competitive landscape remains fluid and the ultimate market leaders have yet to be determined.
Risks & safety
Moderate margin of safety with strong cash position but significant execution risk. • Cash position: $707.1 million in cash and marketable securities as of Q1 2025, providing runway into first half of 2027 • Burn rate: Averaging $95 million per quarter in 2025-2026, with free cash flow of -$149.7 million in Q1 2025 • Debt levels: Low debt-to-equity ratio of 0.15, minimal solvency risk in near term • Current ratio: Strong at 4.9x, indicating solid short-term liquidity • Valuation: Trading at 0.94x book value, negative P/E due to pre-revenue status • Revenue visibility: Limited revenue from collaborations ($16.6 million in Q1 2025), no product sales yet • Clinical risk: Multiple Phase 3 trials ongoing with binary outcomes that could significantly impact valuation • Competition: Intense competition in gene editing space with well-funded rivals
Recent development
Over the past few years, Intellia has executed a strategic transformation from an early-stage research company to a late-stage clinical organization preparing for commercial launches. The company has advanced three programs into Phase 3 clinical trials, representing a significant milestone in its development. The most significant strategic pivot has been the focus on in vivo gene editing, where treatments work directly inside patients' bodies rather than requiring cell extraction and modification. This approach offers greater scalability and broader market potential. The company successfully demonstrated that CRISPR gene editing could work safely and effectively in humans, with NTLA-2001 showing over 90% reduction in disease-causing proteins. Intellia has also made important operational efficiency improvements, including restructuring to reduce operating expenses by 5-10% year-over-year and reducing its real estate footprint to save $50 million in cash. The company discontinued the NTLA-3001 program in favor of a more advanced second-generation approach, demonstrating disciplined resource allocation. The company has been building commercial capabilities in preparation for its first product launch, with NTLA-2002 for hereditary angioedema expected to reach market in the first half of 2027. Management has appointed experienced commercial leaders and is developing U.S. market infrastructure while exploring partnerships for international markets. Recent clinical achievements include dosing the first patients in two separate Phase 3 studies and receiving multiple Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA, which provide expedited regulatory pathways. The company has also expanded its platform capabilities into gene insertion technology, moving beyond simple gene knockout approaches to more sophisticated therapeutic interventions.
NTLA company profile · for informational purposes only — not investment advice.
Track NTLA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free